Renalytix Plc (FRA:2O9)

Market Cap	19.39M -53.6%
Revenue (ttm)	2.55M +35.1%
Net Income	-17.37M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0420
Previous Close	0.0420
Day's Range	0.0420 - 0.0420
52-Week Range	0.0400 - 0.1290
Beta	n/a
RSI	26.92
Earnings Date	Mar 18, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Prepackaged Software
• Founded: 2018
• Employees: 46
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2O9

Financial Performance

In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.

Financial numbers in USD